塞来昔布抑制转移性癌症疼痛的疗效及其胃肠道反应分析  

Analysis of efficacy and gastrointestinal adverse effects of celecoxib in Restraining pain caused by cancer metastasis

作　　者：郑伟华[1] 詹志光[2] 何蕙泾[1] 潘燚[2] 

机构地区：[1]广东省人民医院肿瘤内科,广州510080 [2]广东省人民医院放疗科,广州510080

出　　处：《广东医学》2004年第10期1156-1157,共2页Guangdong Medical Journal

基　　金：广东省科技攻关计划资助项目 (编号 :B3 0 3 0 10 12 )

摘　　要：目的　探讨塞来昔布对抑制晚期癌症患者化疗期间的癌症疼痛的有效性及胃肠道反应。方法　将4 6例轻中度疼痛的癌症患者随机分成塞来昔布 (观察组 )和双氯芬酸钠 (对照组 )进行跟踪治疗及疗效比较 ,并从胃肠道反应、耐受性及安全性等方面加以分析。结果　在止痛方面 ,两组有效率相仿 ,观察组仅引起 19% (6 /31)的一过性胃肠不适 ,未见症状性胃炎及溃疡 (0 /6 ) ,而对照组上消化道症状发生率为 5 3% (8/15 ) ,症状性胃溃疡发生率达 83% (5 /6 ) ,两组比较差异有显著性 (P <0 0 5 )。结论　采用塞来昔布对抑制转移性肿瘤引起的轻中度疼痛具有疗效高、消化道毒副反应小、安全性好的优点。Objective To investigate the efficacy and gastrointestinal adverse effects of Celecoxib in restraining pain caused by cancer metastasis during chemotherapy. Methods Randomized Controlled Trial (RCT) method was used to investigate painkilling scenarios for cancer patients with mild to moderate pain, and to compare the results in terms of side effects, tolerance and safety between two classified groups: Experiment group, using Celecoxib capsules, and the reference group, using Diclofenac Sodium Sustained Release Tablet. Results The effective rate of restraining pain in the two groups was similar; the occurrence of episode gastric and intestinal discomfort was 19.4% (6/31), and no gastritis and ulcer (0/6) occurred in the experiment group; while the occurrence rate of upper gastrointestinal symptoms was 53% (8/15) and the ulcer occurrence was 83% (5/6) in the reference group; all P values were less than 0.05. Conclusion Using celecoxib in restraining mild- moderate pain caused by metastatic tumor has a high effectiveness and little side effects on upper gastrointestinal tract, providing patients with good safety.

关 键 词：塞来昔布 胃肠道反应 癌症疼痛 症状性 转移性癌 对照组 显著性 有效性 

分 类 号：R730[医药卫生—肿瘤] R971[医药卫生—临床医学]